You are here: Industry Insights > Lorbrena

News List

Roche Receives FDA approval for VENTANA ALK CDx Assay with LORBRENA americanpharmaceuticalreview
March 12, 2021
Roche announced US Food and Drug Administration (FDA) approval of the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with Pfizer's drug LORBRENA® ...
Pfizer gets full US FDA nod for LORBRENA as first-line treatment for ALK-Positive metastatic NSCLC expresspharma
March 04, 2021
Approval is based on CROWN trial, which showed a 72 per cent reduction in risk of progression or death for treatment with LORBRENA vs. XALKORI.
Pfizer’s Lorbrena scores US priority review pharmatimes
January 05, 2021
Pfizer’s tyrosine kinase inhibitor (TKI) Lorbrena (lorlatinib) has scored a US Food and Drug Administration (FDA) priority review for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer pharmaceutical-business-review
August 11, 2020
Pfizer announced that the Phase 3 CROWN study of LORBRENA (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) met its primary endpoint by demonstrating significantly ...
FDA green lights Pfizer’s Lorbrena for aggressive lung cancer pharmaphorum
December 12, 2018
Pfizer’s drug Lorbrena (lorlatinib) can be used to treat certain types of advanced lung cancer.The US Food and Drug Administration (FDA) approved the treatment.....